Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

dc.creatorRequejo C.
dc.creatorRuiz-Ortega J.A.
dc.creatorBengoetxea H.
dc.creatorGarcía-Blanco A.
dc.creatorHerrán E.
dc.creatorAristieta A.
dc.creatorIgartua M.
dc.creatorPedraz J.L.
dc.creatorUgedo L.
dc.creatorHernández R.M.
dc.creatorLafuente J.V.
dc.date.accessioned2020-09-02T22:26:54Z
dc.date.accessioned2022-11-08T20:18:14Z
dc.date.available2020-09-02T22:26:54Z
dc.date.available2022-11-08T20:18:14Z
dc.date.created2020-09-02T22:26:54Z
dc.date.issued2017
dc.identifier54, 10, 7722-7735
dc.identifier08937648
dc.identifierhttps://hdl.handle.net/20.500.12728/5974
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5142629
dc.languageen
dc.publisherHumana Press Inc.
dc.subject6-OHDA
dc.subjectGDNF
dc.subjectNeuroregeneration
dc.subjectParkinson’s disease
dc.subjectRostro-caudal gradient
dc.subjectVEGF
dc.subjectdesipramine
dc.subjectdopamine
dc.subjectglial cell line derived neurotrophic factor
dc.subjectglial fibrillary acidic protein
dc.subjectmicrosphere
dc.subjectoxidopamine
dc.subjectpargyline
dc.subjecttyrosine 3 monooxygenase
dc.subjectvasculotropin
dc.subjectglial cell line derived neurotrophic factor
dc.subjectneuroprotective agent
dc.subjectvascular endothelial growth factor A, rat
dc.subjectvasculotropin A
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectArticle
dc.subjectbrain nerve cell
dc.subjectcaudate nucleus
dc.subjectcell count
dc.subjectcontrolled study
dc.subjectcorpus striatum
dc.subjectdisease severity
dc.subjectdopaminergic system
dc.subjectfemale
dc.subjecthistopathology
dc.subjectimmunoreactivity
dc.subjectmedial forebrain bundle
dc.subjectmicroencapsulation
dc.subjectnigroneostriatal system
dc.subjectnonhuman
dc.subjectParkinson disease
dc.subjectpathogenesis
dc.subjectprotein function
dc.subjectputamen
dc.subjectrat
dc.subjectsubstantia nigra
dc.subjectanimal
dc.subjectdrug formulation
dc.subjectparkinsonism
dc.subjectpathology
dc.subjectprocedures
dc.subjectseverity of illness index
dc.subjectSprague Dawley rat
dc.subjecttreatment outcome
dc.subjectAnimals
dc.subjectDrug Compounding
dc.subjectFemale
dc.subjectGlial Cell Line-Derived Neurotrophic Factor
dc.subjectNeuroprotective Agents
dc.subjectParkinsonian Disorders
dc.subjectRats
dc.subjectRats, Sprague-Dawley
dc.subjectSeverity of Illness Index
dc.subjectTreatment Outcome
dc.subjectVascular Endothelial Growth Factor A
dc.titleMorphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors
dc.typeArticle


Este ítem pertenece a la siguiente institución